JAK3 covalent inhibitor 1

SI-8134

JAK3 covalent inhibitor 1, >98% (HPLC)

IUPAC Name : N-((1R,3S)-3-Cyanamido-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-2,3-dihydro-1H-inden-1-yl)-3-fluorobenzenesulfonamide

Price And Availability
Pack Size	Price in USD	Add To Shopping Cart	Availability	Shipping Status
5MG	Request A Quote		Back Order	Estimated to ship on 04 October 2026
10MG	Request A Quote		Back Order	Estimated to ship on 04 October 2026
25MG	Request A Quote		Back Order	Estimated to ship on 04 October 2026
50MG	Request A Quote		Back Order	Estimated to ship on 04 October 2026
100MG	Request A Quote		Back Order	Estimated to ship on 04 October 2026

Applications : This is a selective JAK3 inhibitor, built on a pyrrolo[2,3‑d]pyrimidine scaffold commonly used in JAK‑family inhibitors. Although structurally distinct from approved JAK inhibitors such as baricitinib and ruxolitinib, it aligns mechanistically with ritlecitinib, a highly selective covalent JAK3 inhibitor that targets Cys‑909 of JAK3 . This compound is designed to block JAK3‑dependent cytokine signaling, supporting its use as a tool molecule for studying JAK3‑driven immunological pathways.

References : Hartung V. I. et al.: J. Med. Chem., 66, 9297-9312, 2023.

Storage : Keep container tightly closed under nitrogen or argon and refrigerate for long-term shelf life.

Caution : In case of contact with skin or eyes, rinse immediately with plenty of water and seek medical advice. Wear suitable protective clothing and gloves.